• 15 May 2020 — Thrive Bioscience named one of 50 Fastest Growing Companies of 2020 by Silicon Review.

  • 28 April 2020 — Thrive Bioscience closes on $10.3 million of Convertible Notes and expands its offering by $3.2 million to $13.5 million.

  • 30 March 2020 — Herb Kenny, former Vice President of Global Sales, Scientific Instruments at Thermo Fisher Scientific, joins Thrive Bioscience as Executive Vice President of Commercialization, completing the senior management team for commercializing Thrive’s family of products to significantly improve cell culture.

  • 31 December 2019 — Thrive Bioscience in December completes first five sales of its CellAssist instrument with shipments to commercial customers in Japan, Korea and the U.S.

  • 1 November 2019 — Thrive Bioscience files U.S. patent applications on blockchain and the internet of things (IOT) to cell culture. Thrive’s patent portfolio now consists of over 50 applications related to cell culture of which eight have issued.

  • 9 August 2019 — Thrive Bioscience named one of 20 Most Promising Biotech Solution Providers 2019 and one of 20 Best Biotech Companies of 2019 by CIO (Chief Information Officer) Review.

  • 5 June 2019 — Jeff Goldman, former R&D Manager at Agilent Technologies, joins Thrive Bioscience as Vice President of Engineering & Manufacturing to oversee the productization and manufacturing of Thrive’s family of cell culture instruments.

  • 1 January 2019 — Ira J. Schaefer, Esq., former Partner at Hogan Lovells, joins Thrive Bioscience as Vice President of Intellectual Property to oversee and continue the expansion of Thrive’s intellectual property portfolio.

  • 17 September 2018 — Takashi Kiyoizumi, M.D., Ph.D., M.B.A, joins Thrive Bioscience as Executive Vice President of International and Senior Advisor to CEO.

  • 5 April 2018 — Thrive Bioscience licenses-in on an exclusive basis from an internationally-recognized research institute, an imaging-related portfolio of eight patent applications of which six have issued. Thrive’s patent portfolio now includes 34 patent applications of which seven have issued.

  • 7 July 2016  — Thrive Bioscience announces instruments and services agreement with the Harvard Stem Cell Institute.

  • 1 June 2016 — Thrive Bioscience moves headquarters and laboratory to 11 Audubon Road, Wakefield, Massachusetts.

  • 1 February 2016 – Thrive Bioscience announces completion of $7.2 Million Series A Preferred financing.

  • 18 August 2015 — Thrive Bioscience Raises $4M seed financing.